PNPLA3 I148M polymorphism and progressive liver disease

Two new Later Stone Age sites from the Final Pleistocene in the Falémé Valley, eastern Senegal

Ndiaye, M., Lespez, L., Tribolo, C., Rassé, M., Hadjas, I., Davidoux, S., Huysecom, É., & Douze, K. (2024) · Monash University Research Portal (Monash University) · doi:10.3929/ethz-b-000667478 · Cited by 24,214

Design and validation of a histological scoring system for nonalcoholic fatty liver disease†

Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791

Prevalence of Hepatic Steatosis in An Urban Population in the United States: Impact of Ethnicity

Browning, J. D., Szczepaniak, L. S., Dobbins, R., Nuremberg, P., Horton, J. D., Cohen, J. C., Grundy, S. M., & Hobbs, H. H. (2004) · Hepatology · doi:10.1002/hep.20466 · Cited by 3,664

Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease

Romeo, S., Kozlitina, J., Xing, C., Pertsemlidis, A., Cox, D., Pennacchio, L. A., Boerwinkle, E., Cohen, J. C., & Hobbs, H. H. (2008) · Nature Genetics · doi:10.1038/ng.257 · Cited by 3,416

EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection

European Association for the Study of the Liver (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.02.010 · Cited by 2,918

Nonalcoholic Fatty Liver Disease

Marchesini, G., Brizi, M., Bianchi, G., Tomassetti, S., Bugianesi, E., Lenzi, M., McCullough, A. J., Natale, S., Forlani, G., & Melchionda, N. (2001) · Diabetes · doi:10.2337/diabetes.50.8.1844 · Cited by 2,581

Prevalence of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among a Largely Middle-Aged Population Utilizing Ultrasound and Liver Biopsy: A Prospective Study

Williams, C. D., Stengel, J. Z., Asike, M., Torres, D. M., Shaw, J. C., Contreras, M., Landt, C. L., & Harrison, S. A. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.09.038 · Cited by 2,182

Risk of Cardiovascular Disease in Patients with Nonalcoholic Fatty Liver Disease

Targher, G., Day, C. P., & Bonora, E. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0912063 · Cited by 1,907

Expanding the natural history of nonalcoholic steatohepatitis: From cryptogenic cirrhosis to hepatocellular carcinoma

Bugianesi, E., Leone, N., Vanni, E., Marchesini, G., Brunello, F., CARUCCI, P., Musso, A., Paolis, P. D., Capussotti, L., Salizzoni, M., et al. (2002) · Gastroenterology · doi:10.1053/gast.2002.34168 · Cited by 1,436

Synergistic and Detrimental Effects of Alcohol Intake on Progression of Liver Steatosis

Ciaula, A. D., Bonfrate, L., Krawczyk, M. J., Frühbeck, G., & Portincasa, P. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052636 · Cited by 37

Genetic and Epigenetic Profile of Patients With Alcoholic Liver Disease

Boccuto, L., & Abenavoli, L. (2017) · Annals of Hepatology · doi:10.5604/01.3001.0010.0274 · Cited by 36

The effects of sodium-glucose cotransporter 2 inhibitors on hepatocellular carcinoma: From molecular mechanisms to potential clinical implications

Arvanitakis, K., Koufakis, T., Kotsa, K., & Germanidis, G. S. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106261 · Cited by 37

Omic studies reveal the pathogenic lipid droplet proteins in non-alcoholic fatty liver disease

Zhang, X., Wang, Y., & Liu, P. (2016) · Protein & Cell · doi:10.1007/s13238-016-0327-9 · Cited by 36

Molecular pathogenesis: Connections between viral hepatitis-induced and non-alcoholic steatohepatitis-induced hepatocellular carcinoma

Tian, Z., Chen, X., Yang, P., Lin, Z., Wu, W., Zhang, W., Ding, J. H., Ding, R., Zhang, X., & Dou, K. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.984728 · Cited by 40

Type 2 Diabetes Mellitus and Liver Disease: Across the Gut–Liver Axis from Fibrosis to Cancer

Manilla, V., Santopaolo, F., Gasbarrini, A., & Ponziani, F. R. (2023) · Nutrients · doi:10.3390/nu15112521 · Cited by 37

PNPLA3 148M Carriers with Inflammatory Bowel Diseases Have Higher Susceptibility to Hepatic Steatosis and Higher Liver Enzymes

Mancina, R. M., Spagnuolo, R., Milano, M., Brogneri, S., Morrone, A., Cosco, C., Lazzaro, V., Russo, C., Ferro, Y., Pingitore, P., et al. (2015) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000569 · Cited by 35

Recent advances in hemochromatosis: a 2015 update

Ekanayake, S., Roddick, C., & Powell, L. W. (2015) · Hepatology International · doi:10.1007/s12072-015-9608-2 · Cited by 33

Mutant PNPLA3 I148M protein as pharmacological target for liver disease

Valenti, L. V. C., & Dongiovanni, P. (2017) · Hepatology · doi:10.1002/hep.29298 · Cited by 33

Activation of the Constitutive Androstane Receptor induces hepatic lipogenesis and regulates Pnpla3 gene expression in a LXR-independent way

Marmugi, A., Lukowicz, C., Lasserre, F., Montagner, A., Polizzi, A., Ducheix, S., Goron, A., Gamet‐Payrastre, L., Gerbal‐Chaloin, S., Pascussi, J., et al. (2016) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2016.05.006 · Cited by 32

Genetic and Epigenetic Culprits in the Pathogenesis of Nonalcoholic Fatty Liver Disease

Kovalic, A. J., Banerjee, P., Tran, Q. T., Singal, A. K., & Satapathy, S. K. (2018) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2018.04.001 · Cited by 32

Pathogenesis and remission of type 2 diabetes: what has the twin cycle hypothesis taught us?

Al-Mrabeh, A. H. (2020) · Cardiovascular Endocrinology & Metabolism · doi:10.1097/xce.0000000000000201 · Cited by 35

A Genetic Score Associates With Pioglitazone Response in Patients With Non-alcoholic Steatohepatitis

Kawaguchi‐Suzuki, M., Cusi, K. J., Bril, F., Gong, Y., Langaee, T. Y., & Frye, R. F. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00752 · Cited by 31

PNPLA3 I148M and response to treatment for hepatic steatosis: A systematic review

Boeckmans, J., Gatzios, A., Schattenberg, J. M., Koek, G. H., Rodrigues, R. M., & Vanhaecke, T. (2023) · Liver International · doi:10.1111/liv.15533 · Cited by 31

Non-alcoholic fatty liver disease across endocrinopathies: Interaction with sex hormones

Arefhosseini, S., Ebrahimi‐Mameghani, M., Najafipour, F., & Tutunchi, H. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1032361 · Cited by 31

Nuclear receptors and non-alcoholic fatty liver disease: An update

Xiao, Y., Gonzalez, F. J., Huang, M., & Bi, H. (2020) · Liver Research · doi:10.1016/j.livres.2020.03.001 · Cited by 29

Gut microbiome and nonalcoholic fatty liver disease

Wu, M., & Fan, J. (2023) · Hepatobiliary & pancreatic diseases international · doi:10.1016/j.hbpd.2023.06.006 · Cited by 32

Gene-Environmental Interactions as Metabolic Drivers of Nonalcoholic Steatohepatitis

Albhaisi, S. A. M., & Sanyal, A. J. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.665987 · Cited by 28

The common PNPLA 3 variant p.I148M is associated with liver fat contents as quantified by controlled attenuation parameter ( CAP )

Arslanow, A., Stokes, C. S., Weber, S. N., Grünhage, F., Lammert, F., & Krawczyk, M. J. (2015) · Liver International · doi:10.1111/liv.12937 · Cited by 27

Fatty liver without a large “belly”: Magnified review of non-alcoholic fatty liver disease in non-obese patients

Yousef, M., Juboori, A. A., Albarrak, A. A., Ibdah, J. A., & Tahan, V. (2017) · World Journal of Gastrointestinal Pathophysiology · doi:10.4291/wjgp.v8.i3.100 · Cited by 27

Genetics, Immunity and Nutrition Boost the Switching from NASH to HCC

Dongiovanni, P., Meroni, M., Longo, M., Fargion, S. R., & Fracanzani, A. L. (2021) · Biomedicines · doi:10.3390/biomedicines9111524 · Cited by 27

Hepatic steatosis and PNPLA 3 I148 M variant are associated with serum F etuin‐ A independently of insulin resistance

Rametta, R., Ruscica, M., Dongiovanni, P., Macchi, C., Fracanzani, A. L., Steffani, L., Fargion, S. R., Magni, P., & Valenti, L. V. C. (2014) · European Journal of Clinical Investigation · doi:10.1111/eci.12280 · Cited by 25

Emerging risk factors for nonalcoholic fatty liver disease associated hepatocellular carcinoma

Benhammou, J. N., Lin, J., Hussain, S. K., & El-Kabany, M. M. (2020) · Hepatoma Research · doi:10.20517/2394-5079.2020.16 · Cited by 25

Significance of genetic polymorphisms in patients with nonalcoholic fatty liver disease

Miyaaki, H., & Nakao, K. (2017) · Clinical Journal of Gastroenterology · doi:10.1007/s12328-017-0732-5 · Cited by 26

Nonalcoholic fatty liver disease: one entity, multiple impacts on liver health

Fierbinteanu-Braticevici, C. G., Sinescu, C. J., Moldoveanu, A. C., Petrişor, A., Diaconu, S., Crețoiu, D., & Braticevici, B. (2016) · Cell Biology and Toxicology · doi:10.1007/s10565-016-9361-x · Cited by 24

Cancer of the Liver and its Relationship with Diabetes mellitus

Onikanni, S. A., Lawal, B., Bakare, O. S., Ajiboye, B. O., Ojo, O. A., Farasani, A. M., Kabrah, S. M., Batiha, G. E., & Conte‐Júnior, C. A. (2022) · Technology in Cancer Research & Treatment · doi:10.1177/15330338221119743 · Cited by 24

Towards precision medicine in non-alcoholic fatty liver disease

Francque, S. (2023) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-023-09820-6 · Cited by 25

Destined to develop NAFLD? The predictors of fatty liver from birth to adulthood

Valenti, L. V. C., & Romeo, S. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.06.010 · Cited by 24

Mechanisms of Lipid Droplet Accumulation in Steatotic Liver Diseases

Dempsey, J. L., Ioannou, G. N., & Carr, R. M. (2023) · Seminars in Liver Disease · doi:10.1055/a-2186-3557 · Cited by 24

De Novo and Recurrence of Nonalcoholic Steatohepatitis After Liver Transplantation

Kappus, M. R., & Abdelmalek, M. F. (2017) · Clinics in Liver Disease · doi:10.1016/j.cld.2016.12.006 · Cited by 23

Non-invasive methods to evaluate liver fibrosis in patients with non-alcoholic fatty liver disease

Wang, J., Qin, T., Sun, J.-Y., Li, S., Cao, L., & Lu, X. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.1046497 · Cited by 22

Risk Factors and Clinical Course for Liver Steatosis or Nonalcoholic Steatohepatitis After Living Donor Liver Transplantation

Miyaaki, H., Miuma, S., Taura, N., Shibata, H., Sasaki, R., Soyama, A., Hidaka, M., Takatsuki, M., Eguchi, S., & Nakao, K. (2018) · Transplantation · doi:10.1097/tp.0000000000002319 · Cited by 22

Patatin-like phospholipase domain-containing 3 gene (PNPLA3) polymorphic (rs738409) single nucleotide polymorphisms and susceptibility to nonalcoholic fatty liver disease: A meta-analysis of twenty studies

Zhao, Y. M., Zhao, W., Ma, J., Toshiyoshi, M., & Zhao, Y. (2023) · Medicine · doi:10.1097/md.0000000000033110 · Cited by 20

Comparison of wild-type and high-risk PNPLA3 variants in a human biomimetic liver microphysiology system for metabolic dysfunction-associated steatotic liver disease precision therapy

Xia, M., Varmazyad, M., Plá-Palacín, I., Gavlock, D. C., DeBiasio, R., LaRocca, G. M., Reese, C. E., Florentino, R. M., Faccioli, L. A. P., Brown, J. A., et al. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1423936 · Cited by 22

Future therapy of portal hypertension in liver cirrhosis – a guess

Sauerbruch, T., & Trebicka, J. (2014) · F1000Prime Reports · doi:10.12703/p6-95 · Cited by 21

FibroScan Identifies Patients With Nonalcoholic Fatty Liver Disease and Cardiovascular Damage

Lombardi, R., Petta, S., Pisano, G., Dongiovanni, P., Rinaldi, L., Adinolfi, L. E., Acierno, C., Valenti, L. V. C., Boemi, R., Spatola, F., et al. (2018) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2018.11.011 · Cited by 21

Genetic risk factors associated with NAFLD

Kim, D. Y., & Park, J. Y. (2020) · Hepatoma Research · doi:10.20517/2394-5079.2020.96 · Cited by 20

Effect of PNPLA3 I148M polymorphism on histologically proven non‐alcoholic fatty liver disease in liver transplant recipients

Kim, H., Lee, K., Lee, K., Seo, S., Park, M., Ahn, S. W., Hong, S. K., Yoon, K. C., Kim, H., Choi, Y., et al. (2017) · Hepatology Research · doi:10.1111/hepr.12940 · Cited by 21

Nonalcoholic Fatty Liver Disease in Children.

Sweeny, K. F., & Lee, C. K. (2021) · PubMed Central · Cited by 20

ALDH2 deficiency exacerbates MCD-diet induced MASLD by modulating bile acid metabolism

Luo, J., Lu, Z., Zhong, Z., Pi, M., Xiong, Y., Li, L., Chen, T., Chen, Y., Wang, C., Liu, Z., et al. (2023) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2023.12.017 · Cited by 20

Patatin-like phospholipase domain-containing protein 3 is involved in hepatic fatty acid and triglyceride metabolism through X-box binding protein 1 and modulation of endoplasmic reticulum stress in mice

Ochi, T., Munekage, K., Ono, M., Higuchi, T., Tsuda, M., Hayashi, Y., Okamoto, N., Toda, K., Sakamoto, S., Oben, J. A., et al. (2015) · Hepatology Research · doi:10.1111/hepr.12587 · Cited by 20

The PNPLA3 I148M variant is associated with transaminase elevations in type 2 diabetes patients treated with basal insulin peglispro

Pillai, S., Duvvuru, S., Bhatnagar, P., Foster, W., Farmen, M., Shankar, S., Harris, C., Bastyr, E., Hoogwerf, B., & Haupt, A. (2018) · The Pharmacogenomics Journal · doi:10.1038/tpj.2017.45 · Cited by 19

Advances in Noninvasive Biomarkers for Nonalcoholic Fatty Liver Disease

Gîlcă-Blanariu, G.-E., Budur, D. S., Mitrică, D., Gologan, E., Timofte, O., Bălan, G. G., OLTEANU, V.-A., & Ștefănescu, G. (2023) · Metabolites · doi:10.3390/metabo13111115 · Cited by 21

Experimental Models to Investigate PNPLA3 in Liver Steatosis

Ramandi, A., Diehl, A., Sanyal, A. J., & de Jong, Y. P. (2025) · Liver International · doi:10.1111/liv.70091 · Cited by 19

CAT‐2003: A novel sterol regulatory element‐binding protein inhibitor that reduces steatohepatitis, plasma lipids, and atherosclerosis in apolipoprotein E*3‐Leiden mice

Zimmer, M., Bista, P., Benson, E. L., Lee, D. W., Liu, F., Picarella, D., Vega, R. B., Vu, C. B., Yeager, M., Ding, M., et al. (2017) · Hepatology Communications · doi:10.1002/hep4.1042 · Cited by 21

Endoplasmic reticulum stress at the forefront of fatty liver diseases and cancer

Karin, M., & Kim, J. Y. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100096 · Cited by 20

The 148 M allele of the PNPLA3 is associated with plasma irisin levels in a population sample of Caucasian children: The PANIC Study

Viitasalo, A., Atalay, M., Pihlajamäki, J., Jääskeläinen, J., Korkmaz, A., Kamińska, D., Lindi, V., & Lakka, T. A. (2015) · Metabolism · doi:10.1016/j.metabol.2015.01.010 · Cited by 18

Regulation of retinol‐binding protein 4 and retinol metabolism in fatty liver disease

Romeo, S., & Valenti, L. V. C. (2016) · Hepatology · doi:10.1002/hep.28722 · Cited by 18

Fifteen Years of PNPLA3 : Transforming Hepatology Through Human Genetics

Romeo, S., & Valenti, L. V. C. (2025) · Liver International · doi:10.1111/liv.70240 · Cited by 17

Evolution of liver fibrosis in diabetic patients with NAFLD in a follow-up study: Hepatoprotective effects of sodium-glucose co-transporter-2 inhibitors

Lombardi, R., Mantovani, A., Cespiati, A., Francione, P., Maffi, G., Zanna, E. D., Maffeis, C., Colecchia, A., Passigato, N., Ferrarese, A., et al. (2023) · Digestive and Liver Disease · doi:10.1016/j.dld.2023.09.023 · Cited by 17

Coding variants in PNPLA3 and TM6SF2 are risk factors for hepatic steatosis and elevated serum alanine aminotransferases caused by a glucagon receptor antagonist

Guzmán, C. B., Duvvuru, S., Akkari, P. A., Bhatnagar, P., Battioui, C., Foster, W. M., Zhang, X. M., Shankar, S. S., Deeg, M. A., Chalasani, N., et al. (2018) · Hepatology Communications · doi:10.1002/hep4.1171 · Cited by 17

Interaction between Lifestyle Changes and PNPLA3 Genotype in NAFLD Patients during the COVID-19 Lockdown

Cinque, F., Cespiati, A., Lombardi, R., Costantino, A., Maffi, G., Alletto, F., Colavolpe, L., Francione, P., Oberti, G., Fatta, E., et al. (2022) · Nutrients · doi:10.3390/nu14030556 · Cited by 17

The Association between Pediatric NAFLD and Common Genetic Variants

Umano, G. R., Martino, M., & Santoro, N. (2017) · Children · doi:10.3390/children4060049 · Cited by 16

Associations of TM6SF2 167K allele with liver enzymes and lipid profile in children: the PANIC Study

Viitasalo, A., Pihlajamäki, J., Paananen, J., Atalay, M., Lindi, V., & Lakka, T. A. (2016) · Pediatric Research · doi:10.1038/pr.2016.3 · Cited by 16

Integrated Patient Digital and Biomimetic Twins for Precision Medicine: A Perspective

Miedel, M. T., Schurdak, M. E., Stern, A. M., Soto–Gutiérrez, A., Strobl, E. V., Behari, J., & Taylor, D. L. (2025) · Seminars in Liver Disease · doi:10.1055/a-2649-1560 · Cited by 20

An Overview of Hepatocellular Carcinoma Surveillance Focusing on Non-Cirrhotic NAFLD Patients: A Challenge for Physicians

Cespiati, A., Cinque, F., Meroni, M., Lombardi, R., Dongiovanni, P., & Fracanzani, A. L. (2023) · Biomedicines · doi:10.3390/biomedicines11020586 · Cited by 17

TASL Practice Guidance on the Clinical Assessment and Management of Patients with Nonalcoholic Fatty Liver Disease

Yilmaz, Y. N. (2023) · Hepatology forum/Hepatology forum (Online) · doi:10.14744/hf.2023.2023.0011 · Cited by 15

Chemoprevention of obesity-related liver carcinogenesis by using pharmaceutical and nutraceutical agents

Sakai, H. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i1.394 · Cited by 15

Advances in pediatric non-alcoholic fatty liver disease: From genetics to lipidomics

Riccio, S., Melone, R., Vitulano, C., Guida, P., Maddaluno, I., Guarino, S., Marzuillo, P., del Giudice, E. M., & Sessa, A. D. (2022) · World Journal of Clinical Pediatrics · doi:10.5409/wjcp.v11.i3.221 · Cited by 15

Weight loss induced by bariatric surgery restores adipose tissue PNPLA 3 expression

Wieser, V. E., Adolph, T. E., Enrich, B., Moser, P. L., Moschen, A. R., & Tilg, H. (2016) · Liver International · doi:10.1111/liv.13222 · Cited by 15

Lipid droplet targeting of the lipase coactivator ABHD5 and the fatty liver disease-causing variant PNPLA3 I148M is required to promote liver steatosis

Teskey, G., Tiwari, N., Butcko, A. J., Kumar, A., Yadav, A., Huang, Y. M., Kelly, C. V., Granneman, J. G., Perfield, J. W., & Mottillo, E. P. (2025) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2025.108186 · Cited by 14

Playing Jekyll and Hyde—The Dual Role of Lipids in Fatty Liver Disease

Molenaar, M. R., Penning, L. C., & Helms, J. B. (2020) · Cells · doi:10.3390/cells9102244 · Cited by 12

Nonalcoholic Fatty Liver Disease and Fibrosis Progression: The Good, the Bad, and the Unknown

Harrison, S. A. (2014) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.11.024 · Cited by 13

IRX3 plays an important role in the pathogenesis of metabolic-associated fatty liver disease by regulating hepatic lipid metabolism

Ma, Y., Chen, G., Yi, J., Li, Q., Tan, Z., Fan, W., Luo, X., He, Z., Si, Z., & Li, J. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.895593 · Cited by 12

Impact of Sexual Dimorphism on Therapy Response in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease: From Conventional and Nutritional Approaches to Emerging Therapies

Dileo, E., Saba, F., Parasiliti‐Caprino, M., Rosso, C., & Bugianesi, E. (2025) · Nutrients · doi:10.3390/nu17030477 · Cited by 13

Future Treatment Options and Regimens for Nonalcoholic Fatty Liver Disease

Francque, S., & Ratziu, V. (2023) · Clinics in Liver Disease · doi:10.1016/j.cld.2023.01.010 · Cited by 12

Variability in Phelan‐McDermid syndrome: The impact of the PNPLA3 p.I148M polymorphism

Boccuto, L., Abenavoli, L., Cascio, L., Srikanth, S., DuPont, B. R., Mitz, A. R., Rogers, R. C., & Phelan, K. (2018) · Clinical Genetics · doi:10.1111/cge.13451 · Cited by 12

Metabolic-Associated Fatty Liver Disease in Childhood and Adolescence

Vespoli, C., Iqbal, A. M., Kabbany, M. N., & Radhakrishnan, K. R. (2023) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2023.02.001 · Cited by 11

Interaction between PNPLA3 I148M Variant and Age at Infection in Determining Fibrosis Progression in Chronic Hepatitis C

Nicola, S. D., Dongiovanni, P., Aghemo, A., Cheroni, C., D’Ambrosio, R., Pedrazzini, M., Marabita, F., Donnici, L., Maggioni, M., Fargion, S. R., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0106022 · Cited by 10

Phenotypic Variability in Phelan–McDermid Syndrome and Its Putative Link to Environmental Factors

Boccuto, L., Mitz, A. R., Abenavoli, L., Sarasua, S. M., Bennett, W. E., Rogers, C. R., DuPont, B. R., & Phelan, K. (2022) · Genes · doi:10.3390/genes13030528 · Cited by 10

Gene polymorphisms of Patatin-like phospholipase domain containing 3 (PNPLA3), adiponectin, leptin in diabetic obese patients

Aly, O., Zaki, H. H., Herzalla, M. R., Fathy, A., Raafat, N., & Hafez, M. M. (2020) · PLoS ONE · doi:10.1371/journal.pone.0234465 · Cited by 9

TGF-Β1 & PNPLA3 Genetic Variants and the Risk of Hepatic Fibrosis and HCC in Egyptian Patients with HCV-Related Liver Cirrhosis

Nomair, A. M., Kandil, L. S., Nomeir, H. M., & Kandil, N. S. (2021) · Asian Pacific Journal of Cancer Prevention · doi:10.31557/apjcp.2021.22.10.3317 · Cited by 8

Composite prognostic models across the non-alcoholic fatty liver disease spectrum: Clinical application in developing countries

Luckhoff, H. K. (2015) · World Journal of Hepatology · doi:10.4254/wjh.v7.i9.1192 · Cited by 9

Genomic medicine in hepatology: mechanisms and liver treatment strategies

Kozlov, D., Rodimova, S. A., Filatov, P. V., Mozherov, A. M., Timashev, P. S., Zyuzin, M. V., & Kuznetsova, D. S. (2025) · Molecular Medicine · doi:10.1186/s10020-025-01358-4 · Cited by 9

Genomic Signatures of MASLD: How Genomics Is Redefining Our Understanding of Metabolic Liver Disease

Saliba‐Gustafsson, P., Härdfeldt, J., Pedrelli, M., & Parini, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262210881 · Cited by 9

Polymorphism of the adiponutrin gene (PNPLA3) in the indigenous inhabitants of the Republic of Sakha (Yakutia) with type 2 diabetes mellitus

Алексеевич, К. Х., Sydykova, L. A., Pavlova, N. I., Филиппова, Н. П., Владимирович, Д. В., Apsolikhova, G. A., Соловьева, Н. А., Dyakonova, A. T., Neustroeva, L. M., Варламова, М. А., et al. (2018) · Almanac of Clinical Medicine · doi:10.18786/2072-0505-2018-46-3-258-263 · Cited by 8

Validating candidate biomarkers for different stages of non-alcoholic fatty liver disease

Alqarni, R. B., Iqbal, M. D., Alotaibi, M., Al-Saif, F., Alfadda, A. A., Alkhalidi, H., Bamehriz, F. Y., & Hassanain, M. M. (2020) · Medicine · doi:10.1097/md.0000000000021463 · Cited by 8

Gene-based therapies for steatotic liver disease

Iakovleva, V., & de Jong, Y. P. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.04.024 · Cited by 7

HCC in metabolic syndrome: current concepts and future directions

Zampaglione, L., Ferrari, J., Pedica, F., & Goossens, N. (2021) · Hepatoma Research · doi:10.20517/2394-5079.2021.22 · Cited by 7

Long‐term hypercaloric diet exacerbates metabolic liver disease in PNPLA3 I148M animals

Su, H., Haque, M., Becker, S., Edlund, K., Duda, J., Wang, Q., Reißing, J., Marschall, H., Candels, L. S., Mohamed, M. R., et al. (2023) · Liver International · doi:10.1111/liv.15587 · Cited by 8

Histopathology of Liver Transplantation

Demetris, A. J., Minervini, M. I., Nalesnik, M. A., Randhawa, P. S., & Sasatomi, E. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-0268-8.00084-1 · Cited by 7

Patatin‐like phospholipase domain‐containing protein 3 and Liver Disease: Opportunities to Unravel Mechanisms Underlying Statistical Associations

Boursier, J., & Diehl, A. M. (2014) · Hepatology · doi:10.1002/hep.27445 · Cited by 7

Epidemiology and risk factors for histopathologic characteristics of non‐alcoholic fatty liver disease in South America

Akambase, J. A., Prieto, J. E., de Mattos, Â. Z., de Mattos, Â. A., Carrera, E., Ferrer, J. D., Gallardo, P., Curia, A., Ballerga, E. G., Tovo, C. V., et al. (2023) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17615 · Cited by 6

Pathology of Alcoholic and Nonalcoholic Fatty Liver Disease

Bédossa, P., & Kleiner, D. E. (2015) · Springer eBooks · doi:10.1007/978-3-319-20538-0_12 · Cited by 6

Metabolic-associated fatty liver disease from childhood to adulthood: State of art and future directions

Lanzaro, F., Guarino, S., D’Addio, E., Salvatori, A., D’Anna, J. A., Marzuillo, P., del Giudice, E. M., & Sessa, A. D. (2022) · World Journal of Hepatology · doi:10.4254/wjh.v14.i6.1087 · Cited by 6

Impact of PNPLA3 I148M on alpha-1 antitrypsin deficiency-dependent liver disease progression

Volkert, I., Fromme, M., Schneider, C. V., Candels, L. S., Lindhauer, C., Su, H., Thorhauge, K. H., Pons, M., Mohamed, M., Schneider, K. M., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000574 · Cited by 6

Insulin Resistance in Nonalcoholic Fatty Liver Disease: Experience from Bangladesh

Azam, G., Alam, S., Hasan, S. N., Alam, S. M. N. E., Kabir, J., & Alam, A. K. (2016) · Bangladesh Critical Care Journal · doi:10.3329/bccj.v4i2.30022 · Cited by 6

Triglyceride affects the association between estimated glomerular filtration rate and the onset of non-alcoholic fatty liver disease: A second analysis of a Chinese cohort study

Hu, H., Cao, C., Han, Y. Y., & He, Y. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.984241 · Cited by 5

Communicating PNPLA3 genetic risk status for NAFLD among Mexican-origin men

Villavicencio, E. A., Maldonado, A., Crocker, R. M., Guan, Y., Stallman, C., & Garcia, D. O. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2022.1090101 · Cited by 5

A Defective Circulating Mitochondrial Bioenergetics Profile Reflects the Hepatic One and Outlines Genetic MASLD

Paolini, E., Longo, M., Meroni, M., Podini, P., Maggioni, M., Quattrini, A., Fracanzani, A. L., & Dongiovanni, P. (2025) · Antioxidants · doi:10.3390/antiox14060618 · Cited by 6

Old-fashioned and newly discovered biomarkers: the future of NAFLD-related HCC screening and monitoring

Piciotti, R., Longo, M., Agresta, A., Paolini, E., Cespiati, A., Meroni, M., & Dongiovanni, P. (2022) · Hepatoma Research · doi:10.20517/2394-5079.2022.46 · Cited by 6

Genetic and metabolic factors: the perfect combination to treat metabolic associated fatty liver disease

Meroni, M., Longo, M., & Dongiovanni, P. (2020) · Exploration of Medicine · doi:10.37349/emed.2020.00015 · Cited by 5

Interplay between metabolic dysfunction-associated fatty liver disease and renal function: An intriguing pediatric perspective

Nardolillo, M., Rescigno, F., Bartiromo, M., Piatto, D., Guarino, S., Marzuillo, P., del Giudice, E. M., & Sessa, A. D. (2024) · World Journal of Gastroenterology · doi:10.3748/wjg.v30.i15.2081 · Cited by 5

The I148M PNPLA3 Variant Forces Progressive Portal MASLD by Spatially Perturbing Metabolic Pathways Across Liver Zones

Paolini, E., Meroni, M., Longo, M., Badiali, S., Maggioni, M., Fracanzani, A. L., & Dongiovanni, P. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27031601 · Cited by 4

Metabolic dysfunction-associated steatotic liver disease: pathogenesis and novel treatment options

Ren, R., Liang, X., & Wei, X. (2026) · Molecular Biomedicine · doi:10.1186/s43556-026-00486-5 · Cited by 5

MASLD and the cardiovascular-kidney-liver-metabolic syndrome

Angelidi, A. M., Boutari, C., Kokkorakis, M., Stefanakis, K., Mikhailidis, D. P., Jacob, G., & Mantzoros, C. S. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnag023 · Cited by 6

PNPLA3 polymorphism worsens chemotherapy associated liver injury and affects overall survival in colorectal cancer patients with liver metastasis undergoing hepatic resection

Rumpf, B., Santol, J., Kern, A. E., Ammann, M., Probst, J., Baumgartner, R., Jankoschek, A. S., Podrascanin, V., Lehner, F., Huber, F. X., et al. (2025) · EBioMedicine · doi:10.1016/j.ebiom.2025.105928 · Cited by 4

Comparative efficacy and safety of traditional Chinese patent medicine for NAFLD in childhood or adolescence

Sun, Y., Tan, Z., Jiang, Z., Li, M., Wang, W., Huang, Y., & Sun, J. (2021) · Medicine · doi:10.1097/md.0000000000024277 · Cited by 4

Comparison of Hepatocellular Carcinoma in Hispanics and Non-Hispanics Patients

Asemota, J., Oladunjoye, O. O., Babalola, A., Nwosu, U., Liu, P.-H. S., Oladunjoye, A. O., Castro‐Webb, N., & Miksad, R. A. (2021) · Cureus · doi:10.7759/cureus.14884 · Cited by 4

Effect of Excess Body Weight on the Genetic Susceptibility to Cancer

Burza, M. A., Spagnuolo, R., Montalcini, T., Doldo, P., Pujia, A., & Romeo, S. (2014) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000000237 · Cited by 4

Patatin-like phospholipase domain-containing protein 3 gene I148M polymorphism and its role in liver diseases

Yu, H., Wang, G., & Cheng, Y. (2015) · doi:10.3760/cma.j.issn.1673-4149.2015.05.010

PNPLA3 I148M variant in nonalcoholic fatty liver disease: Demographic and ethnic characteristics and the role of the variant in nonalcoholic fatty liver fibrosis

Chen, L., Xin, Y., Geng, N., Jiang, M., Zhang, D., & Xuan, S. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i3.794 · Cited by 59

PNPLA3 expression and its impact on the liver: current perspectives

Bruschi, F. V., Tardelli, M., Claudel, T., & Trauner, M. (2017) · Hepatic Medicine: Evidence and Research · doi:10.2147/hmer.s125718 · Cited by 81

The PNPLA3 I148M variant and chronic liver disease: When a genetic mutation meets nutrients

Maglio, C., Pirazzi, C., Pujia, A., Valenti, L. V. C., & Romeo, S. (2014) · Food Research International · doi:10.1016/j.foodres.2014.01.055 · Cited by 11

Patatin-like phospholipase domain containing-3 Ile148Met and fibrosis progression after liver transplantation

Valenti, L. V. C., & Fargion, S. R. (2011) · Hepatology · doi:10.1002/hep.24601 · Cited by 10